Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is available in packages of ten 300 mL bottIes (NDC 0270-1410-30). Storage Store at 20-25°C (68-77°F) [See USP]; protect from light.; CYSTOGRAFIN DILUTE 18% - 300ML NDC 0270-1410-30 CYSTOGRAFIN DILUTE 18% 1 Box - 10 BTL x 300ML NDC 0270-1410-30 CYSTOGRAFIN DILUTE 300ML CYSTOGRAFIN DILUTE 1 Box 10 BTL 300ML
- HOW SUPPLIED Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is available in packages of ten 300 mL bottIes (NDC 0270-1410-30). Storage Store at 20-25°C (68-77°F) [See USP]; protect from light.
- CYSTOGRAFIN DILUTE 18% - 300ML NDC 0270-1410-30 CYSTOGRAFIN DILUTE 18% 1 Box - 10 BTL x 300ML NDC 0270-1410-30 CYSTOGRAFIN DILUTE 300ML CYSTOGRAFIN DILUTE 1 Box 10 BTL 300ML
Overview
Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Each mL provides 180 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 85 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen.
Indications & Usage
INDICATION Cystografin Dilute is indicated for retrograde cystourethrography.
Dosage & Administration
Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin Dilute using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full. Radiography: The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered.
Warnings & Precautions
WARNINGS Severe sensitivity reactions are more likely to occur in patients with a personaI or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents. A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.
Contraindications
This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.
Adverse Reactions
Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria. If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs. Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.
Storage & Handling
Storage Store at 20-25°C (68-77°F) [See USP]; protect from light.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.